Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Lowers FY Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Lowers FY Guidance

Myriad Genetics Reports Fiscal Third-Quarter 2015 Financial Results

May 5, 2015 4:05 PM EDT

Total Revenue of $180.0 Million Adjusted Diluted EPS of $0.40 and Diluted EPS of $0.29 myRisk Hereditary Cancer Panel Ended Third Quarter at 58 Percent Conversion Myriad Acquires MVZ Clinic to Facilitate Reimbursement in Germany Company Provides Fiscal Fourth-Quarter 2015 Financial Guidance

SALT LAKE CITY, May 5, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN) today announced financial results for its fiscal third-quarter and nine months ended March 31, 2015, provided an update on recent business highlights and provided fiscal fourth-quarter... More